

Hepatitis C Virus (HCV) Bibliography

May 2018

Essential Overview/Background

1. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. *Gastroenterology*. 2010 Feb;138(2):513–521. doi: 10.1053/j.gastro.2009.09.067. Epub 2009 Oct 25. PMID: 19861128.
2. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. *J Hepatol*. 2014 Feb;60(2):392–420. doi: 10.1016/j.jhep.2013.11.003. Epub 2013 Dec 9. PMID: 24331294.
3. The World Health Organization. Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection. 2016 Apr.
4. Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising Mortality Associated with Hepatitis C Virus in the United States, 2003-2013. *Clin Infect Dis*. 2016 May 15;62(10):1287-1288. doi: 10.1093/cid/ciw111. Epub 2016 Mar 1. PMID: 26936668.
5. Committee on a National Strategy for the Elimination of Hepatitis B and C, Board on Population Health Practice, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. Eliminating the public health problem of hepatitis B and C in the United States: Phase One Report. Washington (DC); 2016 Jun. PMID: 27336113.
6. Joy JB, McCloskey RM, Nguyen T, Liang T, Khudyakov Y, Olmstead A, Krajden M, Ward JW, Harrigan PR, Montaner JSG, Poon AFY. The spread of hepatitis C virus genotype 1a in North America: a retrospective phylogenetic study. *Lancet Infect Dis*. 2016 June;16(6):698-702. doi:10.1016/S1473-3099(16)00124-9. Epub 2016 Mar 30. PMID: 27039040.
7. Goedert JJ. Reconstruction of the hepatitis C virus epidemic in the USA. *Lancet Infect Dis*. 2016 Sep;16(9):1007. doi: 10.1016/S1473-3099(16)30196-7. PMID: 27684343.
8. Kim, A. Hepatitis C Virus. *Ann Intern Med*. 2016 Sep 6;165(5):ITC33-ITC48. doi:10.7326/AITC201609060. PMID: 27595226.
9. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report. National Academies of Sciences, Engineering, and Medicine. Washington, DC: The National Academies Press. 2017.
10. Barocas JA, Linas BP. Decision Science at Work: The Case of Hepatitis C Virus Postexposure Prophylaxis. *Clin Infect Dis*. 2017 Jan 1;64(1):100-101. doi:10.1093/cid/ciw680. Epub 2016 Nov 3. PMID: 27815292.
11. Naggie S, Holland DP, Sulkowski MS, Thomas DL. Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing. *Clin Infect Dis*. 2017 Jan 1;64(1):92-99. Epub 2016 Sep 28. PMID: 27682067.
12. National Viral Hepatitis Action Plan 2017-2020. U.S. Department of Health and Human Services. Jan 2017.
13. Wolitski, R. Report from an Expert Consultation on the Evidence for Early Treatment of HCV in the United States. U.S. Department of Health & Human Services. Feb 2017.

14. Recommendations for Testing, Managing and Treating Hepatitis C [Internet]. AASLD, IDSA, IAS-USA. 2017. September 21, 2017.
15. Hepatitis C: State of Medicaid Access. National Viral Hepatitis Roundtable and the Center for Health Law and Policy Innovation at Harvard Law School. Oct 2017.
16. Lok AS, Chung RT, Vargas HE, Kim AY, Naggie S, Powderly WG. Benefits of Direct-Acting Antivirals for Hepatitis C. *Ann Int Med*. 2017 Dec 5;167(11):812-813. doi:10.7326/M17-1876. Epub 2017 Oct 17. PMID: 29049502.

HCV in Rhode Island

1. Special Section on Hepatitis C. *R I Med J*. 2014; 97(7). ISSN 2327 – 2228.
 - a. Alexander-Scott NE, Lemire A, Larson HE, Bandy U. Prevention and control of hepatitis C in rhode island. *R I Med J (2013)*. 2014 Jul 1;97(7):25-28. PMID: 24983017.
 - b. Joseph R, Kofman A, Larney S, Fitzgerald P. Hepatitis C Prevention and Needle Exchange Program in Rhode Island: ENCORE. *R I Med J (2013)*. 2014 Jul 1;97(7):31-34. PMID: 24983019.
 - c. Kinnard EN, Taylor LE, Galárraga O, Marshall BD. Estimating the true prevalence of hepatitis C in rhode island. *R I Med J (2013)*. 2014 Jul 1;97(7):19-24. PMID: 24983016.
 - d. Taylor LE. Hepatitis C virus infection: from margin to center in rhode island and beyond. *R I Med J (2013)*. 2014 Jul 1;97(7):15-6. PMID: 24983015.
 - e. Taylor LE. What price for a cure? *R I Med J (2013)*. 2014 Jul 1;97(7):16-7. PMID: 25184174.
2. Soipe AI, Razavi H, Razavi-Shearer D, Galárraga O, Taylor LE, Marshall BD. Chronic hepatitis C virus (HCV) burden in Rhode Island: modeling treatment scale-up and elimination. *Epidemiol Infect*. 2016 Aug 5:1-11. [Epub ahead of print]. PMID:27492142
3. Soipe AI, Taylor LE, Abioye AI, Green TC, Hadland SE, Marshall BDL. Prevalence of hepatitis C screening, testing, and care experience among young adults who use prescription opioids nonmedically. *J Adolesc Health*. 2018 Jan;62(1):114-117. doi:10.1016/j.jadohealth.2017.07.018. Epub 2017 Oct 25. PMID: 29102250.

HCV Policy

1. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. *Am J Public Health*. 2000 Oct;90(10):1562-1569. doi:10.2105/ajph.90.10.1562. PMID: 11029989.
2. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. *Hepatology*. 2009 Dec;50(6):1750-1755. doi:10.1002/hep.23220. PMID: 19824079.
3. Arora S, Kalishman S, Thornton K, Dion D, Murata G, Deming P, Parish B, Brown J, Komaromy M, Colleran K, Bankhurst A, Katzman J, Harkins M, Curet L, Cosgrove E, Pak W. Expanding access to hepatitis C virus treatment-Extension for Community Healthcare Outcomes (ECHO) project: Disruptive innovation in specialty care. *Hepatology*. 2010 Sep;52(3):1124-1133. doi:10.1002/hep.23802. PMID: 20607688.

4. Aronsohn A, Jensen D. Distributive justice and the arrival of direct-acting antivirals: who should be first in line? *Hepatology*. 2011 Jun;53(6):1789-1791. doi:10.1002/hep.24374. PMID: 21520197.
5. Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, Parish B, Burke T, Pak W, Dunkelberg J, Kistin M, Brown J, Jenkusky S, Komaromy M, Qualls C. Outcomes of treatment for hepatitis C virus infection by primary care providers. *N Engl J Med*. 2011 Jun 9;364(23):2199-2207. doi:10.1056/nejmoa1009370. Epub 2011 Jun 1. PMID: 21631316.
6. Grebely J, Dore GJ. What Is killing people with hepatitis C virus infection? *Semin Liver Dis*. 2011 Nov;31(4):331-339. doi:10.1055/s-0031-1297922. Epub 2011 Dec 21. PMID: 22189973.
7. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. *Ann Intern Med*. 2012 Feb 21;156(4):271-278. doi:10.7326/0003-4819-156-4-201202210-00004. PMID: 22351712.
8. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, Jewett A, Baack B, Rein DB, Patel N, Alter M, Yartel A, Ward JW, Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. *Morbidity and Mortality Weekly Report*. 2012 Aug 17;61(RR-4):1-32. PMID: 22895429.
9. Ellwood M, Greenwald R, Blankstein SF, Borowsky J, Canton A, Khan S, Villanueva A. Improving the Response to Hepatitis C Virus (HCV) in Massachusetts: Executive Summary. *SHARP: State Healthcare Access Research Project*. Apr 2013.
10. Casalino LP. Professionalism and Caring for Medicaid Patients-- The 5% Commitment? *N Eng J Med*. 2013 Nov 7;369(19):1775-1777. Epub 2013 Oct 9. doi:10.1056/nejmp1310974. PMID: 24106910.
11. Kanwal F, El-Serag HB. Hepatitis C virus treatment: the unyielding chasm between efficacy and effectiveness. *Clin Gastroenterol Hepatol*. 2014;12(8):1381-1383. doi:10.1016/j.cgh.2014.02.031. Epub 2014 Mar 4. PMID: 24607698.
12. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: Is it worth it? *Hepatology*. 2014 Apr;59(4):1246-1249. doi:10.1002/hep.27039. PMID: 24493069.
13. Tsochatzis EA, Crossan C, Longworth L, Gurusamy K, Rodriguez-Peralvarez M, Mantzoukis K, O'Brien J, Thalassinos E, Papastergiou V, Noel-Storr A, Davidson B, Burroughs AK. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. *Hepatology*. 2014 Sep;60(3):832-843. doi:10.1002/hep.27296. Epub 2014 Jul 29. PMID: 25043847.
14. Kottlil S, Wright M, Polis MA, Masur H. Treatment of hepatitis C virus infection: is it time for the internist to take the reins? *Ann Intern Med*. 2014 Sep 16;161(6):443-444. doi:10.7326/m14-0741. PMID: 25222390.
15. Kofman A, Litwin AH, Swan T, Pinkston M, Rizzo B, Bryant V, Taylor LE. Short Communication: Heterogeneity in Drug and Alcohol Use-Related Exclusion Criteria in Direct Acting Antiviral Agent Hepatitis C Treatment Trials for Individuals Coinfected with Hepatitis C Virus and HIV. *Clin Res HIV/AIDS*. 2015;2(2):1019.
16. Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW. The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral Treatments for Hepatitis C Virus. *Clin Infect Dis*. 2015;61(2):157-168. Epub 2015 Mar 16. doi:10.1093/cid/civ220. PMID: 25778747.

17. Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, Avorn J, Choudhry NK. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. *Ann Intern Med.* 2015 Mar 17;162(6):407-419. doi:10.7326/m14-1152. PMID: 25775313.
18. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. *Ann Intern Med.* 2015 Mar 17;162(6):397-406. doi:10.7326/m14-1336. PMID: 25775312.
19. Sidharthan S, Kohli A, Sims Z, Nelson A, Osinusi A, Masur H, Kottlilil S. Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. *Clin Infect Dis.* 2015 Jun 15;60(12):1743-1751. doi:10.1093/cid/civ170. Epub 2015 Mar 2. PMID: 25733369.
20. Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. *Hepatology.* 2015 Jun;61(6):1860-1869. Epub 2015 Mar 16. PMID: 25677072.
21. Improving Patient Access to Hepatitis C Cures: A White Paper From the Hepatitis Therapy Access Physicians Working Group. Hepatitis Work Group: Altice R, Charles D, Fishbein D, Gish R, Kim A, Kobayashi RH, Smith C, Striker R, Vuppalanchi R. 2015 July.
22. Saag MS. Editorial commentary: getting smart in how we pay for HCV drugs: KAOS vs CONTROL. *Clin Infect Dis.* 2015 Jul 15;61(2):169-170. Epub 2015 Mar 16. doi:10.1093/cid/civ221. PMID: 25778748.
23. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. *Ann Intern Med.* 2015 Aug 4;163(3):215-23. doi:10.7326/M15-0406. PMID: 26120969.
24. Chhatwal J, Chen Q, Kanwal F. Why We Should Be Willing to Pay for Hepatitis C Treatment. *Clin Gastroenterol Hepatol.* 2015 Oct;13(10):1711-1713. doi:10.1016/j.cgh.2015.06.005. Epub 2015 Jun 16. PMID: 26091736.
25. Edlin B, Eckhardt B, Shu M, Holmberg S, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. *Hepatology.* 2015 Nov;62(5):1353-1363. doi: 10.1002/hep.27978. PMID: 2729352.
26. Chapko MK, Dufour DR, Hatia RI, Drobeniuc J, Ward JW, Teo CG. Cost-effectiveness of strategies for testing current hepatitis C virus infection. *Hepatology.* 2015 Nov;62(5): 1396-1404. Epub 2015 Aug 25. doi: 10.1002/hep.27966. PMID: 26126725.
27. Ryerson AB, Ehemann CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, Henley SJ, Holtzman D, Lake A, Noone AM, Anderson RN, Ma J, Ly KN, Cronin KA, Penberthy L, Kohler BA. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. *Cancer.* 2016 May 1;122(9): 1312-1337. Epub 2016 Mar 9. doi: 10.1002/cncr.29936. PMID: 26959385.
28. Jena AB, Stevens W, Gonzalez YS, Marx SE, Juday T, Lakdawalla DN, Phillipson TJ. The wider public health value of HCV treatment accrued by liver transplant recipients. *Am J Manag Care.* 2016 May;22(6 Spec Issue No.):SP212-SP219. PMID: 27266951.
29. Linthicum MT, Gonzalez YS, Mulligan K, Moreno GA, Dreyfus D, Juday T, Marx SE, Lakdawalla DN, Edlin BR, Brookmeyer R. Value of expanding HCV screening and treatment policies in the United States. *Am J Manag Care.* 2016 May;22(5 Spec Issue No. 6):SP227-SP235. PMID: 27266953.
30. Lakdawalla DN, Linthicum MT, Vanderpuye-Orgle J. Does patient cost sharing for HCV drugs

- make sense? *Am J Manag Care*. 2016 May;22(6 Spec Issue No.):SP188-SP190. PMID: 27266947.
31. Moreno GA, Mulligan K, Huber C, Linthicum MT, Dreyfus D, Juday T, Marx SE, Gonzalez YS, Brookmeyer R, Lakdawalla DN. Costs and spillover effects of private insurers' coverage of hepatitis C treatment. *Am J Manag Care*. 2016 May;22(6 Spec Issue No.):SP236-SP244. PMID: 27266954.
 32. Edlin B. Access to treatment for hepatitis C virus infection: time to put patients first. *Lancet Infect Dis*. 2016 Sep;16(9):e196-e201. Epub 2016 Jul 13. doi:10.1016/S1473-3099(16)30005-6. PMID: 27421993.
 33. Grebely J, Litwin A, Dore GJ. Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all. *J Viral Hepat*. 2016 Sep;23(9):664-666. Epub 2016 Jun 8. doi:10.1111/jvh.12550. PMID: 27272285.
 34. Levin J, Gonzalez YS, Ingram A, Lindsay C, Parise H, Virabhak S. Early versus delayed hepatitis C treatment provides increased health benefits at lower costs: A UK cost-effectiveness analysis of genotypes 1 and 4 treatment-naïve patients. Conference report at: European Association for the Study of the Liver. April 19-23, 2017.
 35. Lasser KE, Heinz A, Battisti L, Akoumianakis A, Truong V, Tsui J, Ruiz G, Samet JH. A Hepatitis C Treatment Program Based in a Safety-Net Hospital Patient-Centered Medical Home. *Ann Fam Med* 2017 May;15(3):258-261. doi:10.1370/afm.2069. PMID: 28483892.
 36. Cepeda JA, Thomas DL, Astemborski J, Sulkowski MS, Kirk GD, Mehta SH. Increased mortality among persons with chronic hepatitis C with moderate or severe liver disease: a cohort study. *Clin Infect Dis*. 2017 Jul 15;65(2):235-243. doi: 10.1093/cid/cix207. PMID: 28329108.
 37. Kim AY. The National Academy Report on the Elimination of Viral Hepatitis: An Infectious Disease Physician's Perspective. *Clin Infect Dis*. 2017 Sep 1;65(5):709-711. Epub ahead of print. doi: 10.1093/cid/cix501. PMID: 28575213.
 38. Lazarus JV, Wiktor S, Colombo M, Thursz M. Micro-elimination – A path to global elimination of hepatitis C. *J Hepatol*. 2017 Oct;67(4):665-666. Epub 2017 Jul 29. doi:10.1016/j.jhep.2017.06.033. PMID: 28760329.
 39. Mahale P, Engels EA, Li R, Torres HA, Hwang L, Brown EL, Kramer JR. The effects of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. *Gut*. 2018 Mar;67(3):553-561. Epub 2017 Jun 20. doi:10.1136/gutjnl-2017-313983. PMID: 28634198.
 40. Olafsson S, Tyrfinngsson T, Runarsdottir V, Bergmann OM, Hansdottir I, Bjornsson ES, Johannsson B, Sigurdardottir B, Fridriksdottir RH, Love A, Hellard M, Love TJ, Gudnason T, Heimisdottir M, Gottfredsson M. Treatment as prevention for hepatitis C (TraP Hep C) – a nationwide elimination programme in Iceland using direct-acting antiviral agents. *J Int Med*. 2018 May;283(5):500-507. Epub 2018 Mar 7. doi: 10.1111/joim.12740. PMID: 29512219.
 41. Perricone G, Mazzarelli C, Vigano R, Duvoux C, Cortesi P, Facchetti R, Vangeli M, Karam V, Adam R, Strazzabosco M, Belli L. Impact of DAA on liver transplantation: major effects on the evolution of indications and results. A study based on ELTR registry. Conference report at: European Association for the Study of the Liver. April 11-1, 2018.
 42. Pinsky B, Mitchell D, Gonzalez YS, Johnson S, Saab S. Early versus Delayed Hepatitis C Treatment Provides Increased Health Benefits at Lower Costs: A Pan-Genotypic Cost-

Effectiveness Analysis Set in Scotland. Conference report at: European Association for the Study of the Liver. April 11-15, 2018.

43. Sood N, Ung D, Shankar A, Strom BL. A Novel Strategy for Increasing Access to Treatment for Hepatitis C Virus Infection for Medicaid Beneficiaries. *Ann Intern Med.* 2018 May 15. doi:10/7326/M18-0186.

HCV Screening

1. Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. *Clin Infect Dis.* 2012 May;54(9):1259-1271. Epub 2012 Mar 12. doi:10.1093/cid/cis011. PMID: 22412061.
2. Moyer VA, U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Medicine.* 2013 Sep 3;159(5):349. doi:10.7326/0003-4819-159-5-201309030-00672. PMID: 23798026.
3. Ngo-Metzger Q, Ward JW, Valdiserri RO. Expanded hepatitis C virus screening recommendations promote opportunities for care and cure. *Ann Intern Med.* 2013 Sep 3;159(5):364-365. doi:10.7326/0003-4819-159-5-201309030-00675. PMID: 23797155.
4. Taylor LE, Foont JA, DeLong AK, Wurcel A, Linas BP, Chapman S, Maynard MA, Cu-Uvin S, Mayer KH. The spectrum of undiagnosed hepatitis C virus infection in a US HIV clinic. *AIDS Patient Care STDS.* 2014 Jan;28(1):4-9. doi:10.1089/apc.2013.0130. PMID: 24428794.
5. Lushniak BD. Surgeon general's perspectives. *Public Health Rep.* 2014 May;129(3):220-221. doi:10.1177/003335491412900302. PMID: 24790250.
6. Coffin PO, Reynolds A. Ending hepatitis C in the United States: the role of screening. *Hepat Med.* 2014 Jul 3;(6):79-87. doi:10.2147/HMER.S40940. PMID: 25114602.
7. Boschert S. Best HCV value? Screen All Baby Boomers, Treat All. *Internal Medicine News.* 2014 Dec:19-21.
8. Koretz RL, Lin KW, Ioannidis JP, Lenzer J. Is widespread screening for hepatitis C justified? *BMJ.* 2015 Jan 13;350:g7809-g7809. doi:10.1136/bmj.g7809. PMID: 25587052.
9. Smith BD, Yartel AK, Krauskopf K, Massoud OI, Brown KA, Fallon MB, Rein DB. Hepatitis C virus antibody positivity and predictors among previously undiagnosed adult primary care outpatients: cross-sectional analysis of a multisite retrospective cohort study. *Clin Infect Dis.* 2015 Apr;60(8):1145-1152. Epub 2015 Jan 16. doi:10.1093/cid/civ002. PMID: 25595745.
10. Durham DP, Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, Townsend JP. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. *Clin Infect Dis.* 2016 Feb 1;62(3):298-304. Epub 2015 Nov 30. doi:10.1093/cid/civ894. PMID: 26628566.
11. Jonas MC, Rodriguez CV, Redd J, Sloane DA, Winston BJ, Loftus BC. Streamlining Screening to Treatment: The Hepatitis C Cascade of Care at Kaiser Permanente Mid-Atlantic States. *Clin Infect Dis.* 2016 May 15;62(10):1290-1296. Epub 2016 Feb 16. doi:10.1093/cid/ciw086. PMID: 26908812.
12. Frieman JM, Tran TM, Schumacher SG, White LF, Ongarello S, Cohn J, Easterbrook PJ, Linas BP, Denkinger CM. Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection: A Systematic Review and Meta-analysis. *Ann Intern Med.* 2016 Sep 6;165(5):345-355. Epub 2016 Jun 21. doi: 10.7326/M16-0065. PMID: 27322622.

HCV and People who Inject Drugs (PWID)

1. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? *N Engl J Med*. 2001 Jul 19;345(3):211-215. doi:10.1056/nejm200107193450311. PMID: 11463019.
2. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?. *Addiction*. 2004 Sep;99(9):1167-1175. doi:10.1111/j.1360-0443.2004.00821.x. PMID: 15317637.
3. Litwin AH, Soloway I, Gourevitch MN. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. *Clin Infect Dis*. 2005 Apr 15;40 Suppl 5:S339-S345. doi:10.1086/427450. PMID: 15768345.
4. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. *J Sub Abuse Treat*. 2005 Oct;29(3):159-165. doi:10.1016/j.jsat.2005.06.002. PMID: 16183464.
5. Garfein RS, Golub ET, Greenberg AE, Hagan H, Hanson DL, Hudson SM, Kapadia F, Latka MH, Ouellet LJ, Purcell DW, Strathdee SA, Thiede H; DUIT Study Team. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. *AIDS*. 2007 Sep 12;21(14):1923-1932. doi:10.1097/qad.0b013e32823f9066. PMID: 17721100.
6. Sylvestre DL, Zweben JE. Integrating HCV services for drug users: A model to improve engagement and outcomes. *Int J Drug Policy*. 2007 Oct;18(5):406-410. Epub 2007 Apr 30. doi:10.1016/j.drugpo.2007.01.010. PMID: 17854729.
7. Litwin AH, Harris KA Jr., Nahvi S, Philippe J, Zamor MD, Soloway IJ, Tenore PL, Kaswan D, Gourevitch MN, Arnsten JH. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. *J Sub Abuse Treat*. 2009 Jul;37(1):32-40. Epub 2008 Nov 28. doi:10.1016/j.jsat.2008.09.009. PMID: 19038524.
8. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. *Clin Infect Dis*. 2009 Aug 15;49(4):561-573. doi:10.1086/600304. PMID: 19589081.
9. Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, Yeung B, Marks P, van Beek I, McCaughan G, White P, French R, Rawlinson W, Lloyd AR, Kaldor JM; Australian Trial In Acute Hepatitis C Study Group. Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection. *Gastroenterology*. 2010 Jan 1;138(1):123-135.e2. Epub 2009 Sep 24. doi:10.1053/j.gastro.2009.09.019. PMID: 19782085.
10. Harris KA Jr, Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. *J Addic Med*. 2010 Mar;4(1):20-26. doi:10.1097/adm.0b013e3181add3de. PMID: 20485532.
11. Jürgens R, Csete J, Amon JJ, Baral S, Beyrer C. People who use drugs, HIV, and human rights *Lancet*. 2010 Aug 7;376(9739):475-485. doi:10.1016/s0140-6736(10)60830-6. PMID: 20650514.
12. Taylor LE, Bowman SE, Chapman S, Zaller N, Stein MD, Cioe P, Maynard M, McGovern BH. Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy. *Drug Alcohol Depend*. 2011 Jul 1;116(1-3):233-237. Epub 2010 Dec 21.

doi:10.1016/j.drugalcdep.2010.11.016. PMID: 21177046.

13. Higgs P, Sacks-Davis R, Gold J, Hellard M. Barriers to receiving hepatitis C treatment for people who inject drugs: Myths and evidence. *Hepat Mon*. 2011 Jul;11(7):513-518. PMID: 22087188.
14. Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. *Hepatology*. 2012 Jan;55(1):49-57. Epub 2011 Dec 6. doi:10.1002/hep.24656. PMID: 21898506.
15. Stein, MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH. Concurrent group treatment for hepatitis C: Implementation and outcomes in a methadone maintenance treatment program. *J Substance Abuse Treatment*. 2012 Dec;43(4):424-432. Epub 2012 Oct 2. doi: 10.1016/j.jsat.2012.08.007. PMID: 23036920.
16. Grebely J, Oser M, Taylor LE, Dore GJ. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. *J Infect Dis*. 2013 Mar;207 Suppl 1:S19–25. doi:10.1093/infdis/jis928. PMID: 23390301.
17. Treloar C, Rance J, Dore GJ, Grebely J; ETHOS Study Group. Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study. *J Viral Hepat*. 2013 Aug;21(8):560-567. doi:10.1111/jvh.12183. PMID: 24299222.
18. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster Gr, Dillon JF, Goldberg DJ, Dore GJ, Hickman M. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. *Hepatology*. 2013;58(5):1598-1609. Epub 2013 Aug 26. doi:10.1002/hep.26431. PMID: 23553643.
19. *Clinical Infectious Diseases*. 2013;57(Suppl. 2). Full supplement available from: http://cid.oxfordjournals.org/content/57/suppl_2.toc
 - a. Alavi M, Grebely J, Micallef M, Dunlop AJ, Balcomb AC, Day CA, Treloar C, Bath N, Haber PS, Dore GJ, Enhancing treatment for hepatitis C in opioid substitution settings (ETHOS) study group. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS Study. *Clin Infect Dis*. 2013 Aug;57(suppl 2):S62-S69. doi:10.1093/cid/cit305. PMID: 23884068.
 - b. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, Goldbery DJ, Hellard ME. Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-analysis. *Clin Infect Dis*. 2013 Aug;57(suppl 2):S80-S89. doi:10.1093/cid/cit306. PMID: 23884071.
 - c. Bruggmann P, Litwin AH. Models of Care for the Management of Hepatitis C Virus Among People Who Inject Drugs: One Size Does Not Fit All. *Clin Infect Dis*. 2013 Aug;57(suppl 2):S56-S61. doi:10.1093/cid/cit271. PMID: 23884067.
 - d. Cox AL, Thomas DL. Hepatitis C virus vaccines among people who inject drugs. *Clin Infect Dis*. 2013 Aug;57(suppl 2):S46-S50. doi:10.1093/cid/cit329. PMID: 23884065.
 - e. Crawford S, Bath N. Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection. *Clin Infect Dis*. 2013 Aug;57(suppl 2):S75-S79. doi:10.1093/cid/cit297. PMID: 23884070.
 - f. Grady BP, Schinkel J, Thomas XV, Dalgard O. Hepatitis C virus reinfection following treatment among people who use drugs. *Clin Infect Dis*. 2013 Aug;57(suppl 2):S105-

S110. doi:10.1093/cid/cit301. PMID: 23884057.

- g. Grebely J, Bruggmann P, Backmund M, Dore GJ. Moving the agenda forward: the prevention and management of hepatitis C virus infection among people who inject drugs. *Clin Infect Dis*. 2013 Aug;57(suppl 2):S29-S31. doi:10.1093/cid/cit264. PMID: 23884062.
- h. Hilsden RJ, Macphail G, Grebely J, Conway B, Lee SS. Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial. *Clin Infect Dis*. 2013;57(suppl 2):S90-S96. doi:10.1093/cid/cit327. PMID: 23884072.
- i. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. *Clin Infect Dis*. 2013 Aug;57(suppl 2):S39-S45. doi:10.1093/cid/cit296. PMID: 23884064.
- j. Mauss S, Klinker H. Drug-drug interactions in the treatment of HCV among people who inject drugs. *Clin Infect Dis*. 2013 Aug;57(suppl 2):S125-S128. doi:10.1093/cid/cit299. PMID: 23884060.
- k. Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. *Clin Infect Dis*. 2013 Aug;57(suppl 2):S32-S38. doi:10.1093/cid/cit300. PMID: 23884063.
- l. Post JJ, Arain A, Lloyd AR. Enhancing assessment and treatment of hepatitis C in the custodial setting. *Clin Infect Dis*. 2013 Aug;57(suppl 2):S70-S74. doi:10.1093/cid/cit265. PMID: 23884069.
- m. Reimer J, Schmidt CS, Schulte B, Gansefort D, Gözl J, Gerken G, Scherbaum N, Verthein U, Backmund M. Psychoeducation improves hepatitis C virus treatment during opioid substitution therapy: A controlled, Prospective Multicenter Trial. *Clin Infect Dis*. 2013 Aug;57(suppl 2):S97-S104. doi:10.1093/cid/cit307. PMID: 23884073.
- n. Robaey G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, Swan T, Arain A, Kautz A, Stöver H, Wedemeyer H, Schaefer M, Taylor LE, Backmund M, Dalgard O, Prins M, Dore GJ; International Network on Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. *Clin Infect Dis*. 2013 Aug;57(suppl 2):S129-S137. doi:10.1093/cid/cit302. PMID: 23884061.
- o. Schaefer M, Sarkar R, Diez-Quevedo C. Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction. *Clin Infect Dis*. 2013 Aug;57(suppl 2):S111-S117. doi:10.1093/cid/cit266. PMID: 23884058.
- p. Taylor LE, Swan T, Matthews GV. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy. *Clin Infect Dis*. 2013 Aug;57 Suppl 2:S118-24. doi:10.1093/cid/cit326. PMID: 23884059.
- q. Treloar C, Rance J, Backmund M. Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. *Clin Infect Dis*. 2013 Aug;57(suppl 2):S51-S55. doi:10.1093/cid/cit263. PMID: 23884066.

20. Masson CL, Delucchi KL, McKnight C, Hetteema J, Khalili, Min A, Jordan AE, Pepper N, Hall J, Hengl NS, Young C, Shopshire MS, Manuel JK, Coffin L, Hammer H, Shapiro B, Seewald RM, Bodenheimer HC Jr, Sorenson JL, Des Jarlais DC, Perlman DC. A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. *Am J Public Health*. 2013 Oct;103(10):e81-e88. Epub 2013 Aug 15. doi:10.2105/ajph.2013.301458. PMID: 23947319.
21. Grebely J, Dore GJ. Can hepatitis C virus infection be eradicated in people who inject drugs? *Antiviral Res*. 2014 Apr;104:62-72. Epub 2014 Jan 24. doi:10.1016/j.antiviral.2014.01.002. PMID: 24468275.
22. Arain A, Robaey G. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. *World J Gastroenterol*. 2014 Sep 28;20(36):12722-12733. doi:10.3748/wjg.v20.i36.12722. PMID: 25278674.
23. Edlin BR, Winkelstein ER. Can hepatitis C be eradicated in the United States? *Antiviral Res*. 2014 Oct;110:79-93. Epub 2014 Aug 7. doi:10.1016/j.antiviral.2014.07.015. PMID: 25110202.
24. Batchelder AW, Peyser D, Nahvi S, Amsten JH, Litwin AH. "Hepatitis C treatment turned me around:" Psychological and behavioral transformation related to hepatitis C treatment. *Drug Alcohol Depend*. 2015 Aug 1;153:66-71. Epub 2015 Jun 9. doi: 0.1016/j.drugalcdep.2015.06.007. PMID: 26096534.
25. Smith DJ, Combellick J, Jordan AE, Hagan H. Hepatitis C virus (HCV) disease progression in people who injected drugs (PWID): A systematic review and meta-analysis. *Int J Drug Pol*. 2015 Oct;26:911-921. Epub 2015 Jul 26. doi:10.1016/j.drugpo.2015.07.004. PMID: 26298331.
26. Grebely J, Haire B, Taylor LE, Macneill P, Litwin AH, Swan T, Byrne J, Levin J, Bruggmann P, Dore GJ; International Network for Hepatitis in Substance Users. Excluding people who use drugs or alcohol from access to hepatitis C treatments - Is this fair, given the available data? *J Hepatol*. 2015 Oct;63(4):779-82. Epub 2015 Aug 4. doi:10.1016/j.jhep.2015.06.014. PMID: 26254264.
27. Grebely J, Robaey G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Llyod AR, Mauss S, Prins M, Swan T, Schaefer M, Tatlor LE, Dore GJ; International Network for Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. *Int J Drug Policy*. 2015 Oct;26(10):1028-1038. doi:10.1016/j.drugpo.2015.07.005. PMID: 26282715.
28. Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL; C-EDGE CO-STAR Study Group. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy. *Ann Intern Med*. 2016 Nov 1;165(9):625-634. Epub 2016 Aug 9. doi: 10.7326/M16-0816. PMID: 27537841.
29. Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, McNally J, Osinusi A, Brainard DM, Subramanian GM, Natha M, Foster GR, Mangia A, Sulkowski M, Feld JJ. Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. *Clin Infect Dis*. 2016 Dec 1;63(11):1479-1481. Epub 2016 Aug 23. doi: 10.1093/cid/ciw579. PMID: 27553377.
30. Innes H, McAuley A, Alavi M, Valerio H, Goldberg D, Hutchinson SJ. The contribution of health risk behaviors to excess mortality in American adults with chronic hepatitis C: A population

cohort-study. *Hepatology*. 2018 Jan;67(1):97-107. Epub 2017 Nov 16. doi:10.1002/hep.29419. PMID: 28777874.

31. Liang JT, Ward JW. Hepatitis C in Injection-Drug Users – A Hidden Danger of the Opioid Epidemic. *N Eng J Med*. 2018 Mar 29;378(13):1169-1171. doi: 10.1056/NEJMp1716871. PMID: 29601263.
32. Martin SA, Bosse J, Wilson A, Losikoff P, Chiodo L. Under one roof: identification, evaluation, and treatment of chronic hepatitis C in addiction care. *Addict Sci & Clin Pract*. 2018 Apr 25; 13(1):10. doi: 10.1186/s13722-018-0111-7. PMID: 29690936.
33. Jones CM, Einstein EB, Compton WM. Changes in Synthetic Opioid Involvement in Drug Overdose Deaths in the United States, 2010-2016. *JAMA*. 2018 May 1;319(17):1819-1821. doi: 10.1001/jama.2018.2844. PMID: 29715347.

Patient-reported outcomes with DAAs

1. Stepanova M, Thompson A, Doyle J, Younossi I, de Avila L, Younossi ZM. Hepatitis C Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment with Interferon-Free Regimens. *J Infect Dis*. 2018 Mar 13;217(7):1033-1043. doi:10.1093/infdis/jix681. PMID: 29293991.
2. Perumalswami PV, Talal AH. Improvements in Quality of Life: A New Hepatitis C Virus Treatment Indication in Persons with Substance Use Disorders. *J Infect Dis*. 2018 Mar 13;217(7):1020-1023. doi:10.1093/infdis/jix682. PMID: 29294033.

HCV and Alcohol Use

1. Rosman AS, Waraich A, Galvin K, Casiano J, Paronetto F, Lieber CS. Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. *Am J Gastroenterol*. 1996 Mar;91(3):498-505. PMID: 8633498.
2. Corrao G, Aricò S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. *Hepatology*. 1998 Apr;27(4):914-919. doi:10.1097/00042737-199809000-00019. PMID: 9537428.
3. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. *Clin Gastroenterol and Hepatol*. 2005 Nov;3(11):1150-1159. doi:10.1016/s1542-3565(05)00407-6. PMID: 16271348.
4. Anand BS, Currie S, Dieperink E, Bini EJ, Shen H, Ho SB, Wright T, VA-HCV-001 Study Group. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. *Gastroenterology*. 2006 May;130(6):1607-1616. Epub 2006 Mar 6. doi:10.1053/j.gastro.2006.02.023. PMID: 16697724.
5. Singal AK, Anand BS. Mechanisms of synergy between alcohol and hepatitis C virus. *J Clin Gastroenterol*. 2007 Sep;41(8):761-772. doi:10.1097/mcg.0b013e3180381584. PMID: 17700425.
6. Bruggmann P, Dampz M, Gerlach T, Kravec L, Falcato L. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: An analysis of the Swiss Hepatitis C Cohort Study. *Drug Alcohol Depend*. 2010 Jul 1;110(1-2):167-171. Epub 2010 Mar 23. doi:10.1016/j.drugalcdep.2010.02.016. PMID: 20334985.

7. Le Lan C, Guillygomarc'h A, Danielou H, Le Dréau G, Lainé F, Védeilhé C, Deugnier Y, Brissot P, Guyader D, Moirand R. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse. *J Hepatol.* 2012 Feb;56(2):334-340. Epub 2011 Jul 12. doi:10.1016/j.jhep.2011.05.021. PMID: 21756854.
8. Kelly EM, Dodge JL, Bacchetti P, Sarkar M, French AL, Tien PC, Glesby MJ, Golub ET, Augenbraun M, Plankey M, Peters MG. Moderate alcohol use is not associated with fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected women: A prospective cohort study. *Clin Infect Dis.* 2017 Nov 29;65(12): 2050-2056. doi: 10.1093/cid/cix716. PMID: 29020382.

HCV/HIV Coinfection

1. Taylor LE. HIV/viral hepatitis coinfection: the Immunology Center experience. *Med Health R.I.* 2009 Jul;92(7):234-6. PMID: 19685638.
2. Taylor LE, Holubar M, Wu K, Bosch RJ, Wyles DL, Davis JA, Mayer KH, Sherman KE, Tashima KT. Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. *Clin Infect Dis.* 2011 Mar 15;52(6):812-8. Epub 2011 Jan 31. doi:10.1093/cid/ciq201. PMID: 21282184.
3. Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. *Clin Infect Dis.* 2012 Jul;55 Suppl 1:S33-42. doi:10.1093/cid/cis367. PMID: 22715212.
4. Garg S, Taylor LE, Grasso C, Mayer KH. Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. *Clin Infect Dis.* 2013 May;56(10):1480-7. Epub 2013 Feb 5. doi:10.1093/cid/cit054. PMID: 23386630.
5. Taylor LE, Swan T, Matthews GV. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy. *Clin Infect Dis.* 2013 Aug;57 Suppl 2:S118-24. doi:10.1093/cid/cit326. PMID: 23884059.
6. U.S. Department of Health and Human Services Health Resources and Services Administration HIV/AIDS Bureau, Special Projects of National Significance Program. Training and Implementing Guide: Delivering Hepatitis C Treatment in an HIV Care Setting. 2014 Sep.
7. U.S. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents- A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: considerations for antiretroviral use in patients with coinfections. 2014 Nov.
8. Freiman JM, Huang W, White LF, Geng EH, Hurt CB, Taylor LE, Overton ET, Cachay ER, Kitahata MM, Moore RD, Rodriguez B, Mayer KH, Linas BP. Current practices of screening for incident hepatitis C virus (HCV) infection among HIV-infected, HCV-uninfected individuals in primary care. *Clin Infect Dis.* 2014 Dec 15;59(12):1686-1693. Epub 2014 Sep 3. doi:10.1093/cid/ciu698. PMID: 25186591.
9. Graham CS. Hepatitis C and HIV co-infection: closing the gaps. *JAMA.* 2015 Mar 24-31;313(12):1217-1218. doi:10.1001/jama.2015.1111. PMID: 25705993.
10. Mogalian E, Stamm LM, Osinusi A, Brainard DM, Shen G, Ling K, Mathias A. Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and

Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers. *Clin Infect Dis*. 2018 Mar 7. [Epub ahead of print]. doi:10.1093/cid/ciy201. PMID: 29522076.

11. Moore DJ, Jain S, Dube MP, Daar ES, Sun X, Young J, Corado K, Ellorin E, Milam J, Collins D, Blumenthal J, Best BM, Anderson P, Haubrich R, Morris SR. Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study. *Clin Infect Dis*. 2018 May 2;66(10): 1566-1572. doi: 10.1093/cid/cix1055. PMID: 29228144.

Evaluating Fibrosis

1. Holmberg SD, Lu M, Rupp LB, Lamerato LE, Moorman AC, Vijayadeva V, Boscarino JA, Henkle EM, Gordon SC; Chronic Hepatitis Cohort Study (CHeCs) Investigators. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. *Clin Infect Dis*. 2013 Jul;57(2):240-246. Epub 2013 Apr 16. doi:10.1093/cid/cit245. PMID: 23592832.
2. Berenguer J, Zamora FX, Aldámiz-Echevarría T, Von Wichmann MA, Crespo M, López-Aldeguer J, Carrero A, Montes M, Quereda C, Téllez MJ, Galindo MJ, Sanz J, Santos I, Guardiola JM, Barros C, Ortega E, Pulido F, Rubio R, Mallolas J, Tural C, Jurdado JJ, Pérez G, Díez C, Álvarez-Pellicer J, Esteban H, Bellón JM, González-García J; Grupo de Estudio del SIDA (GESIDA) HIV/HCV Cohort Study Group. Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfecting with HIV and hepatitis C virus. *Clin Infect Dis*. 2015 Mar 15;60(6):950-958. Epub 2014 Nov 24. doi:10.1093/cid/ciu939. PMID: 25422386.
3. Smith DJ, Combellick J, Jordan AE, Hagan H. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. *Int J Drug Policy*. 2015 Oct;26(10):911-921. Epub 2015 Jul 26. doi:10.1016/j.drugpo.2015.07.004. PMID: 26298331.

HCV and Cirrhosis

1. Ge PS, Runyon BA. Serum ammonia level for the evaluation of hepatic encephalopathy. *JAMA*. 2014 Aug 13;312(6):643-644. doi:10.1001/jama.2014.2398. PMID: 25117134.
2. Yadav A, Vargas HE. Care of the patient with cirrhosis. *Clin Liver Dis*. 2015 May 7;5(4):100-104. doi:10.1002/cl.462.

Vetted Websites

- <http://ridefeatshepc.com/>
- <http://www.cdc.gov/hepatitis/hcv/>
- <http://www.who.int/hepatitis/en/>
- <http://www.treatmentactiongroup.org/hcv>
- <http://www.natap.org/>
- <http://hcvadvocate.org/>
- <http://www.oasiscliniconline.org/>

- <http://www.hivandhepatitis.com/>
- <http://nvhr.org/>
- <http://www.hepeducation.org/>
- <http://hcvtreatmentaccess.org/>